drugset / Trial / NCT00971191

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

NCT00971191 ↗

Phase 1 Terminated 22 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelBasic science

Summary

This study will enroll patients who are planned to undergo surgical removal of their tumor. The goal of the study is to evaluate the changes that occur in the tumor after brief (about 8 days) exposure to the study drug.

Timeline

Start
2010-02
Primary completion
2012-04
Completion
2012-05

Outcome

Outcome not reported

Stopped: “See termination reason in detailed description.”

Drugs

EvaluationDrugModalityDoseRoute
Subject DACOMITINIB ANHYDROUS Small molecule — —